Novo Nordisk Slashes Wegovy Price by 50% Amid Sharp Stock Decline

Novo Nordisk has announced a significant 50% price reduction for its popular weight-loss medication, Wegovy. This strategic move comes as the pharmaceutical giant faces mounting political and regulatory pressure regarding drug pricing. The price cut coincides with a period of severe market volatility for the company, with its stock price plunging 22% over the past week. Over the last year, NVO shares have lost approximately 56% of their value, currently trading near their 52-week lows. Analysts suggest that while the price reduction may address regulatory concerns, it poses a substantial threat to future profit margins and revenue growth. Investors remain cautious as the company navigates these headwinds in a highly competitive weight-loss drug market.